VIVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. VIVS just made an extreme one-day jump (~+72% regular session) and is technically stretched (RSI ~84) while the broader trend remains bearish (SMA200 > SMA20 > SMA5). With no Intellectia buy signals and pattern-based odds pointing to near-term pullback, the higher-probability outcome is a fade from these levels rather than a clean continuation. For an impatient investor, the risk/reward at $2.90 is unfavorable—better to avoid new entries here (or take profits if already long).
Price/Trend: Massive spike to $2.90 from $1.70 (+71.76%) into the close; post-market slightly red (-0.66%). Despite the spike, moving averages are bearish (SMA200 > SMA20 > SMA5), implying the bigger-picture trend is still down and this may be a sharp counter-trend move. Momentum: MACD histogram is positive and expanding (0.0506), showing short-term momentum is bullish, but RSI(6)=83.816 signals overbought conditions and elevated pullback risk. Levels: Pivot 2.364. Immediate resistance R1 3.013 then R2 3.415; near-term support S1 1.715 (roughly prior close zone) then S2 1.313. At $2.90, price is close to R1 (overhead supply likely). Quant/Pattern read: Similar-pattern analysis suggests ~70% probability of -4.01% next day, -8.37% next week, -9.99% next month—consistent with a post-spike mean reversion. Intellectia Proprietary Trading Signals: No signal on given stock today. (AI Stock Picker: no signal; SwingMax: no recent signal.)
Expanded NAMKind services into Asia-Pacific via authorized distributors (Korea/China) with JCBio and Tekon Biotech—potentially supports longer-term commercial reach and business development momentum.
Short-term momentum tailwind from the large price surge may attract brief follow-through buying.
Overbought technical condition after a +70%+ day increases probability of a sharp pullback.
Primary trend is still bearish based on moving averages, suggesting the move could be a temporary spike rather than a durable reversal.
News feed includes unrelated SanDisk items, implying limited company-specific catalyst depth beyond the distribution expansion.
Hedge funds and insiders show neutral activity (no supportive accumulation signal).
Latest quarter (2026/Q2): Revenue fell to $28,000 (-6.67% YoY). Net loss widened slightly to -$2.545M (-0.16% YoY). EPS declined to -0.98 (-42.35% YoY). Gross margin reported at 100 (+3.44% YoY), but the company is still deeply unprofitable with a very small revenue base—fundamentals do not currently justify chasing a sudden price spike.
No analyst rating or price target change data was provided. With no visible Wall Street coverage signals in the dataset, there is no confirmable pro/cons consensus from analysts to support buying after today’s surge.
